DalsnaFinance

ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

Markets PR Newswire By PR Newswire 22 Jun 2026 09:14 1 min read
ChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig Therapeutics

SAN DIEGO, June 22, 2026 /PRNewswire/ -- ChemDiv, Inc. (www.chemdiv.com), a global provider of integrated drug discovery solutions, today announced significant milestones achieved through its proprietary central nervous system (CNS) focused drug discovery platform. The ChemDiv-built...

SAN DIEGO, June 22, 2026 /PRNewswire/ -- ChemDiv, Inc. (www.chemdiv.com), a global provider of integrated drug discovery solutions, today announced significant milestones achieved through its proprietary central nervous system (CNS) focused drug discovery platform. The ChemDiv-built...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.